[EGFR-mutation in non-small cell lung carcinoma. Treatment with tyrosine kinase inhibitors possible]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations represents a distinct subtype.
• These tumors are more prevalent in women, non-smokers, and Asian populations, often presenting as adenocarcinoma with a favorable prognosis.
• Activating EGFR mutations lead to enhanced signal transduction, making tumors highly responsive to tyrosine kinase inhibitors (TKIs).

Purpose of the Study:

• To highlight the significance of EGFR mutation status in NSCLC treatment decisions.
• To recommend EGFR mutation analysis for patients with incurable NSCLC, excluding specific subtypes.
• To discuss various methods for detecting EGFR mutations.

Main Methods:

• Polymerase Chain Reaction (PCR) based techniques are employed for mutation detection.
• Methods include sequence analysis, high-resolution melting (HRM) with sequence analysis, and DXS gene scan.
• These molecular techniques are crucial for identifying actionable EGFR mutations.

Main Results:

• Activating EGFR mutations predict a high response rate to EGFR-TKIs.
• First-line treatment with EGFR-TKIs is indicated for NSCLC with activating EGFR mutations.
• EGFR mutation analysis is vital for guiding therapeutic strategies.

Conclusions:

• EGFR mutation analysis is crucial for optimizing treatment in NSCLC.
• It is recommended for all patients with incurable NSCLC, except for squamous cell carcinoma, carcinoid, and mucinous bronchiolo-alveolar cell carcinoma.
• Targeted therapy with EGFR-TKIs offers significant benefits for patients with identified EGFR mutations.